UNLABELLED: Xanthinurias are rare inherited disorders of purine metabolism. Xanthinuria type III is caused by molybdenum cofactor deficiency (MoCD) due to pathogenic variants in MOCS1, MOCS2, MOCS3, or GEPH genes. Here, we described five Roma patients from four unrelated families with hypouricemia, accumulation of xanthine/hypoxanthine, deficiency of xanthine oxidase activity, variable age of diagnosis, and only asymptomatic or mild clinical course. Whole exome sequencing was performed on all probands, aged 3 to 43 years, due to lack of genetic confirmation for xanthinuria types I and II. The causality of the putative pathogenic variant was confirmed by analysis of sulfite and related metabolites and in vitro functional characterization of metal-binding pterin (MPT) synthesis and protein complex formation. Considering the rarity of the condition and recessive inheritance, 34 candidate variants were identified after filtering out allele frequency threshold in non-Finnish Europeans. An ultra-rare MOCS2 variant rs776441627 in two overlapping reading frames (c.244A > T (NM_176806.4; p.Ile82Phe) = c.57A > T (NM_004531.5; p.Leu19Phe)) segregated with the disease in all five patients (four homozygotes, one compound heterozygote). The variant has an allele frequency of 3.6% in a Roma population control group. Functional characterization revealed the significantly decreased MPT synthesis activity and confirmed the causality of rs776441627 in MoCD. CONCLUSION: The rs776441627 is a functional variant for MoCD with a mild to asymptomatic clinical phenotype and fully penetrant biochemical phenotype. Hypouricemia should be considered in the differential diagnostic algorithm of pediatric and adult patients with neurological symptoms, and MOCS2 should be considered in gene panels for xanthinuria screening. WHAT IS KNOWN: • Xanthinuria type III is caused by molybdenum cofactor deficiency (MoCD) due to pathogenic variants in MOCS1, MOCS2, MOCS3, or GEPH genes. • The majority of patients with xanthinuria III present with classical early-onset MoCD due to autosomal recessive variants in the MOCS1 gene, manifesting severe progressive neurological complications during the first postnatal days. • To date, approximately 40 patients with MoCD due to pathogenic MOCS2 variants have been reported; most were diagnosed during the neonatal period with intractable seizures and feeding disorders. WHAT IS NEW: • A novel ultra-rare variant, rs776441627, located in two overlapping reading frames of the MOCS2, was identified in five Roma patients presenting a mild to asymptomatic clinical MoCD phenotype and a fully penetrant biochemical phenotype. • Functional studies of p.Ile82Phe (small MOCS2A subunit) and p.Leu19Phe (large MOCS2B subunit) demonstrate a strong reduction in molydopterin synthase complex formation and activity, consistent with the changes in biomarkers of MoCD observed in affected individuals. • The rs776441627 variant shows significantly elevated frequency among the Roma population, highlighting the importance of considering ethnic background in the differential diagnosis of MoCD. • Hypouricemia may provide an initial, generally available biochemical key marker indicator of molybdenum cofactor deficiency.

Cancer Innovation Laboratory Center for Cancer Research National Cancer Institute Frederick MD USA

Children's Faculty Hospital Kosice Košice Slovakia

Department of Pediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Pharmacology Ajou University School of Medicine 164 World Cup Ro Yeongtong Gu Suwon South Korea

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Faculty of Medicine University Ss Cyril and Methodius 1000 Skopje North Macedonia

Institute of Biochemistry Department of Chemistry and Center for Molecular Medicine University of Cologne Cologne Germany

Institute of Rheumatology Na Slupi 4 128 50 Prague Czech Republic

Molecular Genetic Epidemiology Section Basic Research Laboratory National Cancer Institute Frederick MD USA

Zobrazit více v PubMed

Ichida K et al (1997) Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J Clin Invest 99(10):2391–2397 PubMed PMC

Ichida K et al (2001) Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem Biophys Res Commun 282(5):1194–1200 PubMed

Sebesta I, Stiburkova B, Krijt J (2018) Hereditary xanthinuria is not so rare disorder of purine metabolism. Nucleosides Nucleotides Nucleic Acids 37(6):324–328 PubMed

Reiss J et al (1998) Mutations in a polycistronic nuclear gene associated with molybdenum cofactor deficiency. Nat Genet 20(1):51–53 PubMed

Mechler K et al (2015) Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency. Genet Med 17(12):965–970 PubMed

Kožich V et al (2022) Human ultrarare genetic disorders of sulfur metabolism demonstrate redundancies in H(2)S homeostasis. Redox Biol 58 PubMed PMC

Johannes L, Fu CY, Schwarz G (2022) Molybdenum cofactor deficiency in humans. Molecules 27(20):6896. 10.3390/molecules27206896 PubMed PMC

Reiss J (2000) Genetics of molybdenum cofactor deficiency. Hum Genet 106(2):157–163 PubMed

Schwarz G, Mendel RR, Ribbe MW (2009) Molybdenum cofactors, enzymes and pathways. Nature 460(7257):839–847 PubMed

Reiss J et al (1998) Genomic structure and mutational spectrum of the bicistronic MOCS1 gene defective in molybdenum cofactor deficiency type A. Hum Genet 103(6):639–644 PubMed

Gutzke G et al (2001) Thiocarboxylation of molybdopterin synthase provides evidence for the mechanism of dithiolene formation in metal-binding pterins. J Biol Chem 276(39):36268–36274 PubMed

Belaidi AA, Schwarz G (2013) Molybdenum cofactor deficiency: metabolic link between taurine and S-sulfocysteine. Adv Exp Med Biol 776:13–19 PubMed

Misko AL et al (2020) Delineating the phenotypic spectrum of sulfite oxidase and molybdenum cofactor deficiency. Neurol Genet 6(4) PubMed PMC

Lee EJ et al (2021) Rare cause of xanthinuria: a pediatric case of molybdenum cofactor deficiency B. CEN Case Rep 10(3):378–382 PubMed PMC

Spiegel R et al (2022) Molybdenum cofactor deficiency: a natural history. J Inherit Metab Dis 45(3):456–469 PubMed PMC

Hughes EF et al (1998) Molybdenum cofactor deficiency-phenotypic variability in a family with a late-onset variant. Dev Med Child Neurol 40(1):57–61 PubMed

Mize C, Johnson JL, Rajagopalan KV (1995) Defective molybdopterin biosynthesis: clinical heterogeneity associated with molybdenum cofactor deficiency. J Inherit Metab Dis 18(3):283–290 PubMed

Scelsa B et al (2019) Mild phenotype in molybdenum cofactor deficiency: a new patient and review of the literature. Mol Genet Genomic Med 7(6) PubMed PMC

Stiburkova B et al (2021) Renal hypouricemia 1: rare disorder as common disease in Eastern Slovakia Roma population. Biomedicines 9(11):1607. 10.3390/biomedicines9111607 PubMed PMC

Mraz M et al (2015) Modern diagnostic approach to hereditary xanthinuria. Urolithiasis 43(1):61–67 PubMed

Krijt J, Vackova M, Kozich V (2001) Measurement of homocysteine and other aminothiols in plasma: advantages of using tris(2-carboxyethyl)phosphine as reductant compared with tri-n-butylphosphine. Clin Chem 47(10):1821–1828 PubMed

Kozich V et al (2019) Metabolism of sulfur compounds in homocystinurias. Br J Pharmacol 176(4):594–606 PubMed PMC

Kozich V et al (2022) Human ultrarare genetic disorders of sulfur metabolism demonstrate redundancies in H(2)S homeostasis. Redox Biol 58 PubMed PMC

Stiburkova B et al (2012) Novel mutations in xanthine dehydrogenase/oxidase cause severe hypouricemia: biochemical and molecular genetic analysis in two Czech families with xanthinuria type I. Clin Chim Acta 413(1–2):93–99 PubMed

Jurecka A et al (2010) Xanthine dehydrogenase deficiency with novel sequence variations presenting as rheumatoid arthritis in a 78-year-old patient. J Inherit Metab Dis 33(Suppl 3):S21–S24 PubMed

Stiburkova B et al (2018) Thiopurine-induced toxicity is associated with dysfunction variant of the human molybdenum cofactor sulfurase gene (xanthinuria type II). Toxicol Appl Pharmacol 353:102–108 PubMed

MacArthur DG et al (2014) Guidelines for investigating causality of sequence variants in human disease. Nature 508(7497):469–476 PubMed PMC

Yang Y et al (2013) Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med 369(16):1502–1511 PubMed PMC

Ichida K et al (2012) Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans. Int J Mol Sci 13(11):15475–15495 PubMed PMC

Cha DH et al (2019) Contribution of SLC22A12 on hypouricemia and its clinical significance for screening purposes. Sci Rep 9(1):14360 PubMed PMC

Kim Y, Han BG, KoGES group (2017) Cohort profile: the korean genome and epidemiology study (KoGES) consortium. Int J Epidemiol 46(4):1350. 10.1093/ije/dyv316 PubMed PMC

Vuong H et al (2015) AVIA v2.0: annotation, visualization and impact analysis of genomic variants and genes. Bioinformatics 31(16):2748–2750 PubMed PMC

Adzhubei IA et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7(4):248–249 PubMed PMC

Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7):1073–1081 PubMed

Schwarz JM et al (2014) MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 11(4):361–362 PubMed

Rentzsch P et al (2019) CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res 47(D1):D886–D894 PubMed PMC

Shihab HA et al (2013) Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat 34(1):57–65 PubMed PMC

Richards S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424 PubMed PMC

Manichaikul A et al (2010) Robust relationship inference in genome-wide association studies. Bioinformatics 26(22):2867–2873 PubMed PMC

Edwards M et al (2015) Investigation of molybdenum cofactor deficiency due to MOCS2 deficiency in a newborn baby. Meta Gene 3:43–49 PubMed PMC

Llamas A, Mendel RR, Schwarz G (2004) Synthesis of adenylated molybdopterin: an essential step for molybdenum insertion. J Biol Chem 279(53):55241–55246 PubMed

Hahnewald R et al (2006) A novel MOCS2 mutation reveals coordinated expression of the small and large subunit of molybdopterin synthase. Mol Genet Metab 89(3):210–213 PubMed

Santamaria-Araujo JA, Wray V, Schwarz G (2012) Structure and stability of the molybdenum cofactor intermediate cyclic pyranopterin monophosphate. J Biol Inorg Chem 17(1):113–122 PubMed

Kuper J et al (2000) Mutations in the molybdenum cofactor biosynthetic protein Cnx1G from Arabidopsis thaliana define functions for molybdopterin binding, molybdenum insertion, and molybdenum cofactor stabilization. Proc Natl Acad Sci U S A 97(12):6475–6480 PubMed PMC

Atwal PS, Scaglia F (2016) Molybdenum cofactor deficiency. Mol Genet Metab 117(1):1–4 PubMed

Bayram E et al (2013) Molybdenum cofactor deficiency: review of 12 cases (MoCD and review). Eur J Paediatr Neurol 17(1):1–6 PubMed

Alkufri F et al (2013) Molybdenum cofactor deficiency presenting with a parkinsonism-dystonia syndrome. Mov Disord 28(3):399–401 PubMed

Arican P et al (2019) The clinical and molecular characteristics of molybdenum cofactor deficiency due to MOCS2 mutations. Pediatr Neurol 99:55–59 PubMed

Johnson JL et al (2001) Molybdopterin synthase mutations in a mild case of molybdenum cofactor deficiency. Am J Med Genet 104(2):169–173 PubMed

Megahed H et al (2016) Utility of whole exome sequencing for the early diagnosis of pediatric-onset cerebellar atrophy associated with developmental delay in an inbred population. Orphanet J Rare Dis 11(1):57 PubMed PMC

Arranz JA et al (2010) Deficiency of molybdenum cofactor biosynthesis due to a novel mutation in the MOCS2 genes in a child with short stature. J Inherit Metab Dis 33(1):S32–S32

Morar B et al (2004) Mutation history of the roma/gypsies. Am J Hum Genet 75(4):596–609 PubMed PMC

Stiburkova B et al (2016) Prevalence of URAT1 allelic variants in the Roma population. Nucleosides Nucleotides Nucleic Acids 35(10–12):529–535 PubMed

Stiburkova B et al (2013) Novel allelic variants and evidence for a prevalent mutation in URAT1 causing renal hypouricemia: biochemical, genetics and functional analysis. Eur J Hum Genet 21(10):1067–1073 PubMed PMC

Claverie-Martin F et al (2018) URAT1 and GLUT9 mutations in Spanish patients with renal hypouricemia. Clin Chim Acta 481:83–89 PubMed

Farrell S et al (2021) Regulatory news: Nulibry (fosdenopterin) approved to reduce the risk of mortality in patients with molybdenum cofactor deficiency type A: FDA approval summary. J Inherit Metab Dis 44(5):1085–1087 PubMed